Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy.

Corrado TinterriAndrea SagonaErika BarbieriSimone Di Maria GrimaldiFlavia JacobsAlberto ZambelliRubina Manuela TrimboliDaniela BernardiValeriano VinciDamiano Gentile

Published in: Cancers (2022)

No specific subgroup of de novo MBC patients showed a statistically significant survival advantage after FLC followed by LRT of the primary tumor.

Keyphrases

metastatic breast cancer
patients undergoing
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
randomized controlled trial
combination therapy
placebo controlled
double blind